Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 936-946

  Kühnel, Florian ^a   Gürlevik, Engin ^a   Wirth, Thomas C ^b   Strüver, Nina ^a   Malek, Nisar P ^a   Müller Schilling, Martina ^c   Manns, Michael P ^a   Carnero, Amancio ^d   Zender, Lars ^a   Kubicka, Stefan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GAL4; TRANSCRIPTION FACTOR KRAB; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSENSOR; CONTROLLED STUDY; GENE REPRESSION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LIVER INJURY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN TARGETING; TOXICITY TESTING; TUMOR XENOGRAFT; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; DNA VIRUSES; MUS;

EID: 77952010973     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.298     Document Type: Article

References (44)

1. Hurtado Picó, A, Wang, X, Sipo, I, Siemetzki, U, Eberle, J, Poller, W et al. (2005). Viral and nonviral factors causing nonspecific replication of tumor-and tissue-specific promoter-dependent oncolytic adenoviruses. Mol Ther 11:563-577.
2. Bilsland, AE, Merron, A, Vassaux, G and Keith, WN (2007). Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 67:1299-1307.
3. Levine, AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
4. Fridman, JS and Lowe, SW (2003). Control of apoptosis by p53. Oncogene 22:9030-9040.
5. Harada, JN and Berk, AJ (1999). p53-Independent and-dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73:5333-5344.
6. O'Shea, CC, Soria, C, Bagus, B and McCormick, F (2005). Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8:61-74.
7. Zheng, X, Rao, XM, Gomez-Gutierrez, JG, Hao, H, McMasters, KM and Zhou, HS (2008). Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 82:3415-3427.
8. Thomas, MA, Broughton, RS, Goodrum, FD and Ornelles, DA (2009). E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus. J Virol 83:2406-2416.
9. Lowe, SW, Bodis, S, McClatchey, A, Remington, L, Ruley, HE, Fisher, DE et al. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
10. Kubicka, S, Kühnel, F, Zender, L, Rudolph, KL, Plümpe, J, Manns, M et al. (1999). p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J Biol Chem 274:32137-32144.
11. Wirth, T, Kühnel, F, Fleischmann-Mundt, B, Woller, N, Djojosubroto, M, Rudolph, KL et al. (2005). Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 65:7393-7402.
12. Kühnel, F, Zender, L, Wirth, T, Schulte, B, Trautwein, C, Manns, M et al. (2004). Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways. Cancer Gene Ther 11:28-40.
13. Shimada, A, Kato, S, Enjo, K, Osada, M, Ikawa, Y, Kohno, K et al. (1999). The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59:2781-2786. (Pubitemid 29283107)
14. Flores, ER, Tsai, KY, Crowley, D, Sengupta, S, Yang, A, McKeon, F et al. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564.
15. Agami, R, Blandino, G, Oren, M and Shaul, Y (1999). Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399:809-813.
16. Gong, JG, Costanzo, A, Yang, HQ, Melino, G, Kaelin, WG Jr., Levrero, M et al. (1999). The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809.
17. Yuan, ZM, Shioya, H, Ishiko, T, Sun, X, Gu, J, Huang, YY et al. (1999). p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-817.
18. Steegenga, WT, Shvarts, A, Riteco, N, Bos, JL and Jochemsen, AG (1999). Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins. Mol Cell Biol 19:3885-3894.
19. Gressner, O, Schilling, T, Lorenz, K, Schulze Schleithoff, E, Koch, A, Schulze-Bergkamen, H et al. (2005). TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24:2458-2471.
20. Lin, KW, Nam, SY, Toh, WH, Dulloo, I and Sabapathy, K (2004). Multiple stress signals induce p73beta accumulation. Neoplasia 6:546-557.
21. Sayan, AE, Paradisi, A, Vojtesek, B, Knight, RA, Melino, G and Candi, E (2005). New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun 330:186-193.
22. Lokshin, M, Tanaka, T and Prives, C (2005). Transcriptional regulation by p53 and p73. Cold Spring Harb Symp Quant Biol 70:121-128.
23. Schaack, J, Maguire, HF and Siddiqui, A (1996). Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenovirus infection. Virology 216:425-430.
24. Löser, P, Jennings, GS, Strauss, M and Sandig, V (1998). Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 72:180-190.
25. Hall, AR, Dix, BR, O'Carroll, SJ and Braithwaite, AW (1998). p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 4:1068-1072.
26. Rothmann, T, Hengstermann, A, Whitaker, NJ, Scheffner, M and zur Hausen, H (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470-9478.
27. Dix, BR, O'Carroll, SJ, Myers, CJ, Edwards, SJ and Braithwaite, AW (2000). Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 60:2666-2672.
28. O'Shea, CC, Johnson, L, Bagus, B, Choi, S, Nicholas, C, Shen, A et al. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611-623.
29. Hobom, U and Dobbelstein, M (2004). E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol 78:7685-7697.
30. Koch, P, Gatfield, J, Löber, C, Hobom, U, Lenz-Stöppler, C, Roth, J et al. (2001). Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. Cancer Res 61:5941-5947.
31. Ramachandra, M, Rahman, A, Zou, A, Vaillancourt, M, Howe, JA, Antelman, D et al. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19:1035-1041.
32. Kaelin, WG Jr. (1999). The p53 gene family. Oncogene 18:7701-7705.
33. Tomasini, R, Tsuchihara, K, Wilhelm, M, Fujitani, M, Rufini, A, Cheung, CC et al. (2008). TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677-2691.
34. Mills, AA, Zheng, B, Wang, XJ, Vogel, H, Roop, DR and Bradley, A (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
35. Yang, A, Schweitzer, R, Sun, D, Kaghad, M, Walker, N, Bronson, RT et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718.
36. Yang, A, Walker, N, Bronson, R, Kaghad, M, Oosterwegel, M, Bonnin, J et al. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
37. Gaiddon, C, Lokshin, M, Ahn, J, Zhang, T and Prives, C (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874-1887.
38. Bergamaschi, D, Gasco, M, Hiller, L, Sullivan, A, Syed, N, Trigiante, G et al. (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402.
39. Irwin, MS, Kondo, K, Marin, MC, Cheng, LS, Hahn, WC and Kaelin, WG Jr. (2003). Chemosensitivity linked to p73 function. Cancer Cell 3:403-410.
40. Rocco, JW, Leong, CO, Kuperwasser, N, DeYoung, MP and Ellisen, LW (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45-56.
41. Costanzo, A, Merlo, P, Pediconi, N, Fulco, M, Sartorelli, V, Cole, PA et al. (2002). DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9:175-186.
42. Mizuguchi, H and Kay, MA (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:2577-2583.
43. Vayssade, M, Haddada, H, Faridoni-Laurens, L, Tourpin, S, Valent, A, Bénard, J et al. (2005). P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 116:860-869.
44. Zhang, YA, Nemunaitis, J, Samuel, SK, Chen, P, Shen, Y and Tong, AW (2006). Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 66:9736-9743.